Home > Boards > Other Markets > Foreign Stock Markets > PAION AG Aachen (PA8)

YICHANG HUMANWELL RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Leff0815 Member Profile
 
Followed By 1
Posts 29
Boards Moderated 0
Alias Born 08/05/13
160x600 placeholder
Leff0815   Thursday, 07/23/20 05:06:48 PM
Re: None
Post # of 55 
YICHANG HUMANWELL RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN CHINA


The third marketing approval of remimazolam and the second in procedural sedation is a major milestone on the path to bringing this novel anesthetic to patients around the world, and we both congratulate Yichang Humanwell on this achievement, and await their confirmation of the marketing approval”, Dr. Jim Phillips, CEO of PAION AG, commented. “We anticipate the roll-out of remimazolam in China still in the second half of 2020.”

reference

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences